ArticlePloS one2019

Lubiprostone as a potential therapeutic agent to improve intestinal permeability and prevent the development of atherosclerosis in apolipoprotein E-deficient mice.

Kentaro Arakawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.